公司概述
Corbus Pharmaceuticals Holdings, Inc. is a clinical stage biotechnology entity dedicated to the development and commercialization of therapeutics targeting oncology and metabolic disorders, specifically obesity. The company operates within the broader Healthcare sector and the specialized Biotechnology industry, positioning itself to leverage biological innovations for high-value medical treatments. As of the latest data, the enterprise possesses a market capitalization of $183.04M while maintaining a workforce of 36 employees. These figures indicate a small-cap, early-stage organization where the market cap reflects investor valuation of the pipeline rather than current cash-flow generation, and the lack of reported annual revenue underscores the clinical nature of its operations prior to commercial product launch. The scale of the company is defined by its resource-intensive research phase, evidenced by the significant burn rate relative to its modest cash reserves and minimal headcount.
财务健康
The company's financial statements reveal a Net Income (TTM) of $-78,537,000 and an EBITDA of $-85,077,000, with reported Revenue (TTM) listed as N/A. The substantial gap between the negligible revenue and the deep net loss highlights a cost structure dominated by research and development expenditures necessary to advance clinical candidates like CRB-701. Free Cash Flow stands at $-37,728,752, indicating a continuous consumption of cash reserves which limits immediate financial flexibility but is typical for clinical-stage assets. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded as 0.0%, reflecting that the company has not yet generated commercial sales to cover its operating expenses. On the balance sheet, the company holds $163.27M in cash against $1.63M in debt, resulting in a Debt to Equity ratio of 1.11. Despite the high debt-to-equity figure, the liquidity position appears robust given the massive cash buffer relative to liabilities. The Current Ratio is 8.07, suggesting a very strong short-term liquidity position capable of covering current obligations many times over. Return on Equity is -54.2% and Return on Assets is -32.9%, metrics that reveal the company is currently destroying equity value per dollar invested as it prioritizes pipeline advancement over profitability.
估值评估
Valuation multiples for Corbus are constrained by its lack of earnings, with a P/E Ratio (TTM) listed as N/A and a Forward P/E of -2.11. The negative forward P/E implies that the market is not pricing in near-term earnings growth but rather evaluating the asset based on pipeline potential and cash burn dynamics. The Price to Book ratio is 1.23, indicating that the market values the company at a slight premium over its net asset value, which includes its cash and intangible assets. Alternative valuation metrics such as the Price to Sales ratio (N/A) and EV/EBITDA (-0.25) further reflect the pre-revenue status where traditional profitability-based multiples are inapplicable or negative. The stock price has historically ranged between a 52-Week High of $20.56 and a 52-Week Low of $5.12. Without a specific current price to calculate the exact percentage deviation, the valuation is inherently volatile, trading within a range that reflects the high risk associated with clinical-stage biotechnology. The Beta is 2.79, signifying that the stock's price volatility is significantly higher than the broader market, moving with much greater intensity to news regarding clinical trial outcomes or regulatory approvals.
Growth & Income
Revenue Growth (YoY) and Earnings Growth (YoY) are both listed as N/A, which is consistent with the company's status as a pre-revenue clinical stage entity. Since there is no baseline revenue or earnings to compare against, calculating growth rates is mathematically impossible at this stage of the business lifecycle. As a non-dividend payer, the company maintains a Dividend Yield of N/A and a Payout Ratio of 0.0%, meaning it reinvests all available capital into research activities rather than distributing income to shareholders. This reinvestment strategy is essential for advancing its pipeline of antibody drug conjugates, though it precludes any current income generation for investors. The overall growth and income profile is characterized by high uncertainty and zero current yield, with future performance entirely dependent on the successful progression of its therapeutic candidates through clinical trials.